Source link : https://www.newshealth.biz/health-news/radionuclide-containing-combo-slows-metastatic-prostate-cancer-improves-survival/
Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived significantly longer when they received enzalutamide (Xtandi) plus radium-223 (Ra-223, Xofigo), a large randomized trial showed. Median radiographic progression-free survival (rPFS), the primary endpoint, improved from 16.4 months with enzalutamide along with 19.4 months with the addition of Ra-223. Median overall […]
Author : News Health
Publish date : 2024-09-15 20:21:55
Copyright for syndicated content belongs to the linked Source.
inHealth